- Oops!Something went wrong.Please try again later.
Unless you borrow money to invest, the potential losses are limited. But if you pick the right stock, you can make a lot more than 100%. For example, the IDEAYA Biosciences, Inc. (NASDAQ:IDYA) share price had more than doubled in just one year - up 178%. Also pleasing for shareholders was the 40% gain in the last three months. We'll need to follow IDEAYA Biosciences for a while to get a better sense of its share price trend, since it hasn't been listed for particularly long.
Because IDEAYA Biosciences made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
Take a more thorough look at IDEAYA Biosciences' financial health with this free report on its balance sheet.
A Different Perspective
IDEAYA Biosciences shareholders should be happy with the total gain of 178% over the last twelve months. A substantial portion of that gain has come in the last three months, with the stock up 40% in that time. This suggests the company is continuing to win over new investors. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 4 warning signs for IDEAYA Biosciences you should be aware of, and 1 of them is concerning.
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.